SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

March 11, 2013 07:00 ET

Implant Sciences to Present at Global Security Asia 2013 Conference

WILMINGTON, MA--(Marketwire - Mar 11, 2013) -  Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that the Company will be an exhibitor and presenter at Global Security Asia 2013 from April 2nd to 4th, 2013, in Singapore. At the conference, Implant Sciences' Marketing Director, Brad Chase, will deliver a presentation titled, "Integrating Explosives Trace Detection into Building Security." Both the Company's recently TSA-approved Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detector, and its handheld Quantum Sniffer QS-H150 will be displayed at the conference in booth #1817.

Global Security Asia is Asia Pacific's premier conference on internal security and counter terrorism. The conference brings together leading experts and specialists in the fields of counter terrorism, internal state security, and civil defense. These experts present papers addressing some of the challenges and threats that the Asia Pacific region currently faces. Papers and presentations, such as the one to be given by Implant Sciences, highlight state-of-the-art technologies and services currently available to counter threats.

Implant Sciences' presentation will explore the issues of integrating explosives trace detection (ETD) into building security through a review of how ETD was deployed at an event where numerous heads of state and foreign dignitaries were in attendance -- the sixth Summit of the Americas, held in Cartegena, Columbia in April of 2012. The planning, operations, and results of security operations at the summit will be covered, including:

  • Overview of activities leading up to the Summit of the Americas
  • Examination of the different ways in which trace detection was used during the event
  • Analysis of the explosive detection incidents that occurred during the event
  • Review of the lessons learned from security operations at the summit

"Our paper and case study were selected for presentation by a panel of security experts for the Global Security Asia conference. We are pleased to share the experience of Implant Sciences' customers in the effective use of explosives trace detection in a layered security environment," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "Implant Sciences has had significant success in the Asian marketplace and we are delighted to have been asked to present our technology at this Conference."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact